DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The presentation will take place Monday, September 9^th at 3:15 p.m. EDT in Room 7.02 at the Millennium Broadway Hotel in New York City.  The presentation will be webcast live at http://wsw.com/webcast/rrshq23/DMPI and available for 90 days.

Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's timely progress in developing important, new chemotherapies for patients who have little to no therapeutic options. 

DelMar's lead drug, VAL-083, is being developed to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 is approved in China to treat chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and in the United States.

Developing Essential New Treatments for Aggressive Brain Cancers

Fifty percent of patients with GBM will fail today's approved therapies, Temodar^® and Avastin^®.  Tumor resistance to Temodar is well documented and known to be caused by the MGMT enzyme. Studies by the National Cancer Institute and DelMar have shown that VAL-083 acts through a unique mechanism unaffected by MGMT and has activity against a range of cancers. 

DelMar is conducting a Phase I/II clinical trial to assess the safety and efficacy of VAL-083 as a potential new treatment for GBM patients who have failed standard therapies. In June, DelMar reported encouraging interim results from the trial at the American Society for Clinical Oncology (ASCO). Last month, the FDA allowed DelMar to accelerate the dose-escalation in the clinical trial.

Temodar generates more than US$950 million annually in global revenues, primarily from the treatment of brain cancer.

In addition to its clinical activities in the United States, DelMar has acquired the commercial rights to VAL-083 in China, where it is approved for chronic myelogenous leukemia (CML) and lung cancer. DelMar and its manufacturing partner, Guangxi Wuzhou Pharmaceuticals, plan to work with leading clinicians in China to develop new post-market data to support the sales and marketing of VAL-083 in these indications in China and to expand the market opportunities for the drug on a worldwide basis.

DelMar's Recent Highlights:

• August: FDA Allows Accelerated Dose-escalation for VAL-083 Clinical Trial in Gliobastoma
• July: VAL-083 Clinical Trial in Glioblastoma Expands to UC San Francisco (UCSF)
• July: DelMar and Guangxi Wuzhou Announce Chinese Government Funding Award
• July: First U.S. Patent Issued for VAL-083, Part of International IP Strategy

Follow us on Twitter @DelMarPharma and use #Rodman2013 for conference updates.  

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com

SOURCE DelMar Pharmaceuticals